Home Newsfeeds Redburn Partners Reinstates Neutral on Omnicom Group

Redburn Partners Reinstates Neutral on Omnicom Group

Redburn Partners analyst Bianca Dallal reinstates Omnicom Group (NYSE:OMC) with a Neutral.

byBenzinga Newsdesk

September 8, 2022

1 minute read

Redburn Partners analyst Bianca Dallal reinstates Omnicom Group (NYSE:OMC) with a Neutral.

Analyst Ratings

What 4 Analyst Ratings Have To Say About Amkor Tech

By Benzinga Insights

April 30, 9:00 AM

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Amkor Tech…

AMKR

Apellis Pharma Shares Jump As FDA Accepts Its Lead Product Application For Eye Disease

By Vandana Singh

November 18, 1:12 PM

The FDA has accepted for review Apellis Pharmaceuticals Inc’s (NASDAQ:APLS) unsolicited major amendment to the New Drug Application (NDA) for intravitreal…

APLS

Unique Logistics International Announcesd Merger Agreement with Edify Acquisition Corp.

By Charles Gross

December 19, 7:03 AM

Unique Logistics International, Inc. (OTCMKTS: UNQL) ("Unique" or the "Company"), a global logistics and freight forwarding company, today announced that it has signed a definitive agreement and plan of merger (the "Merger Agreement") with Edify Acquisition Corp.

EAC

European Commission Approves Gilead’s Trodelvy For Pre-Treated HR+/HER2- Metastatic Breast Cancer

By Happy Mohamed

July 27, 1:24 PM

-- Approval Based on Clinically Meaningful Overall Survival Benefit Demonstrated in the TROPiCS-02 Study in Pre-Treated HR+/HER2- (IHC 0, IHC 1+ or IHC 2+/ISH–) Metastatic Breast Cancer vs. Physician's Choice

GILD

Redburn Partners Reinstates Neutral on Omnicom Group

Related Posts

What 4 Analyst Ratings Have To Say About Amkor Tech

Apellis Pharma Shares Jump As FDA Accepts Its Lead Product Application For Eye Disease

Unique Logistics International Announcesd Merger Agreement with Edify Acquisition Corp.

European Commission Approves Gilead’s Trodelvy For Pre-Treated HR+/HER2- Metastatic Breast Cancer